Navigation Links
ImMAGE Biotherapeutics Closes Out 2016 in France as a YEi Laureate
Date:2/16/2017

PHILADELPHIA, Feb. 16, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today their completion of the YEi Start in France program.

The YEi Start in France program is an accelerator designed to help entrepreneurs grow their business in France and Europe.  ImMAGE Biotherapeutics was one of eight American companies selected to complete an intensive one week immersion in France in December that provided introductions to an extensive customized business network and connections to the best resources in Europe.

"It was an honor to be included among the eight YEi laureates in 2016," said ImMAGE Biotherapeutics President and COO Mahesh Narayanan. "During the course of the program, I had the opportunity to meet with influential companies and investors, including potential partners and mentors that can support our potential expansion overseas."

Narayanan visited a number of research and cancer centers that could be potential clinical sites for ImMAGE in the future.  Among the centers were Gustave Roussy, a major cancer center in Europe that specializes in breast cancer, especially with early stage clinical trials; EFS, an immunotherapy research center; and CGFL, a research institute that specializes in using imaging to study biodistribution of drugs.

In addition, Narayanan met with companies that have potential to collaborate with ImMAGE, including Onxeo, an orphan oncology drug development company with four drugs currently in the pipeline, and Oncodesign, a preclinical contract research organization.

ImMAGE plans to start collaborating with many of these institutions over the next 12 months. Gustave Roussy and CHUV/CGFL are potential clinical sites for Europe. Oncodesign is a potential collaborator for the non-GLP efficacy studies, while Onxeo might be an early partner for future development of various candidates.

About ImMAGE Biotherapeutics
ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com

CONTACT: Zhi Mou, 1-866-692-2939

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immage-biotherapeutics-closes-out-2016-in-france-as-a-yei-laureate-300408909.html


'/>"/>
SOURCE ImMAGE Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. ImMAGE Biotherapeutics to Present at the 9th Annual Biotech Showcase Conference
2. ImMAGE Biotherapeutics Announces Positive Results from Animal Studies
3. ImMAGE Biotherapeutics Announces Positive Results from In Vitro Trials
4. How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma
5. Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans
6. Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics
7. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
8. Biotech Stocks on Investors Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma
9. Stealth BioTherapeutics To Present At 28th Annual Piper Jaffray Healthcare Conference
10. Stealth BioTherapeutics To Present At Stifel 2016 Healthcare Conference
11. Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK Business ... US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants module ... and biologic sealants used in surgical applications. BioMedGPS estimates the market will grow ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):